China Shineway Pharmaceutical Group Limited

SEHK:2877 Rapport sur les actions

Capitalisation boursière : HK$6.6b

China Shineway Pharmaceutical Group Résultats passés

Passé contrôle des critères 5/6

China Shineway Pharmaceutical Group a connu une croissance annuelle moyenne de ses bénéfices de 20.8%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 5.7% par an. Les revenus ont augmenté de en hausse à un taux moyen de 13.4% par an. Le rendement des capitaux propres de China Shineway Pharmaceutical Group est 15.1% et ses marges nettes sont de 26.3%.

Informations clés

20.8%

Taux de croissance des bénéfices

21.6%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie5.6%
Taux de croissance des recettes13.4%
Rendement des fonds propres15.1%
Marge nette26.3%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Oct 18
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%

If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity

Jun 03
If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity

Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?

May 13
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?

China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461

Apr 26
China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461

Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?

Apr 17
Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?

China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461

Mar 31
China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461

China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings

Mar 14
China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings

Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?

Jan 29
Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?

China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly

Sep 28
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly

China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118

Sep 01
China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118

We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Aug 03
We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?

May 30
Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?

We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Mar 07
We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125

Sep 01
China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125

China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 31
China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet

Apr 07
China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet

China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.

Mar 11
China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.

Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?

Feb 18
Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?

Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?

Jan 31
Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?

Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?

Jan 13
Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?

What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?

Dec 25
What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?

We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease

Dec 10
We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease

Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years

Nov 25
Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years

Ventilation des recettes et des dépenses

Comment China Shineway Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SEHK:2877 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 244,2051,1052,111107
31 Mar 244,3611,0372,212109
31 Dec 234,5179702,314110
30 Sep 234,5259262,318124
30 Jun 234,5348832,323137
31 Mar 234,2428032,215127
31 Dec 223,9517232,107117
30 Sep 223,7186512,004117
30 Jun 223,4855791,902116
31 Mar 223,3545681,832115
31 Dec 213,2245571,763113
30 Sep 213,1224531,676109
30 Jun 213,0203501,590105
31 Mar 212,8383221,528102
31 Dec 202,6562951,466100
30 Sep 202,5923821,42588
30 Jun 202,5284691,38477
31 Mar 202,6174861,39390
31 Dec 192,7065031,402103
30 Sep 192,6705201,367102
30 Jun 192,6335371,332100
31 Mar 192,6025211,293114
31 Dec 182,5705061,254128
30 Sep 182,4925161,174136
30 Jun 182,4135261,095144
31 Mar 182,166489929120
31 Dec 171,92045276397
30 Sep 171,89747470881
30 Jun 171,87349665366
31 Mar 171,93354265170
31 Dec 161,99358964874
30 Sep 161,93556965979
30 Jun 161,87754966984
31 Mar 161,96660367376
31 Dec 152,05565867869
30 Sep 152,14767269173
30 Jun 152,23968570578
31 Mar 152,23469570179
31 Dec 142,22970569780
30 Sep 142,22870469779
30 Jun 142,22770369878
31 Mar 142,20769369981
31 Dec 132,18768470183

Des revenus de qualité: 2877 a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 2877 sont plus élevées que l'année dernière 2877. (26.3%) sont plus élevées que l'année dernière (19.5%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de 2877 ont augmenté de manière significative de 20.8% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de 2877 au cours de l'année écoulée ( 25.1% ) dépasse sa moyenne sur 5 ans ( 20.8% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices 2877 au cours de l'année écoulée ( 25.1% ) a dépassé celle du secteur Pharmaceuticals 9.4%.


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de 2877 ( 15.1% ) est considéré comme faible.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé